Human Cell Based Protein Turnover Assays

Targeted Protein Degradation is an exciting, emerging therapeutic modality targeting endogenous protein homeostasis pathway to modulate protein turnover. One approach for Targeted Protein Degradation uses small molecules such as bi-functional degraders or molecular glues that can redirect the ubiquitin-proteasome mediated degradation pathway and trigger the degradation of specific proteins in a highly selective and effective manner. This new approach has expanded the druggable target space by allowing drugs to modulate protein turnover or the depletion of over-abundant proteins that have been associated with disease states such as cancer (oncoproteins) or Alzheimer’s Disease (TAU protein).
 
Eurofins Discovery LeadHunter^™ Solutions offers a rapidly growing portfolio of Protein Turnover Biosensor Assays for accelerated screening of small molecule therapeutics and quantifying changes in endogenous protein levels in disease-relevant cell models. These fully optimized assays detect protein turnover induced by targeted degrader molecules, such as bifunctional degraders, with higher sensitivity and more rapid kinetics than phenotypic endpoint assays (e.g., cell proliferation).
 
Human Cell Based Protein Turnover assay platform enables sensitive quantitation of protein degradation of targets with our EFC-based cellular biosensor cell lines that combine EFC detection technology with CRISPR genome editing.